Gene therapy research for GM2 gangliosidosis
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at the potential of gene therapy to treat GM2 gangliosidosis, a rare inherited disease that affects the brain and nerves. By studying blood samples, researchers hope to learn more about how the disease works and whether gene therapy might be a future treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of GM2 gangliosidosis (like Tay-Sachs or Sandhoff disease).
- You must be at least 5 years old.
- A blood sample must already be planned as part of your regular care.
- If you are a minor, you must weigh at least 25 kg (about 55 pounds).
- You must not be under legal guardianship or curatorship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
This trial tests giving a gene therapy directly to a baby before birth to treat GM1 gangliosidosis, a rare genetic condition that damages the brain and body. The treatment aims to replace the missing enzyme to help the baby develop healthier.
This study follows people with gangliosidosis to better understand how the condition changes over time. You may be asked to complete thinking/behavior tests and, if you have late-onset disease, get a head MRI (a painless scan) to help researchers track changes in the brain.
This trial tests a new gene therapy (VGN-R08b) for infants with Type 2 Gaucher disease, a rare genetic condition that affects the brain and body. The goal is to see if the treatment is safe and can help improve symptoms.
This trial tests a new gene therapy (VGM-R02b) for children with Glutaric Acidemia Type 1 (GA-1) whose symptoms are not well controlled by standard treatment. The goal is to see if the therapy is safe and can help improve neurological symptoms.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
Hear when a new Tay-Sachs Disease Ganglioside trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.